A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

Abstract Background Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of durable immune memory, but vaccines alone have shown sparse clinical act...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall, Craig L. Slingluff
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2017-11-01
Serija:	Journal for ImmunoTherapy of Cancer
Teme:	Breast cancer immunotherapy cancer vaccine cytotoxic T-cell lymphocyte response peptide poly-ICLC
Online dostop:	http://link.springer.com/article/10.1186/s40425-017-0295-5
Oznake:	Označite Brez oznak, prvi označite!